

**List of International Collaborative Research Projects Approved by HMSC  
during meeting held on 13<sup>th</sup> July, 2021 (through VC)**

S. No.	Details of the Project	
1.	Comparison of Metabolomics Profiles Between Patients with Proliferative and Membranous Lupus Nephritis in London and New Delhi	
	<p><b>Principal Investigator</b></p> <p>Dr. Ranjan Gupta</p> <p>Assistant Professor All India Institute of Medical Sciences (AIIMS), New Delhi-110029</p>	<p><b>Funding/Collaborating Agency</b></p> <p>AIIMS-UCL Collaborative Research Grant</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 5,00,000</p> <p><b>Duration</b>                      41 Months</p> <p><b>Subject area</b>                 Rheumatology</p>
	Approved .	
2.	Exploring empathy, advocacy, and neglect in the context of neglected tropical diseases: A mixed methods study from India	
	<p><b>Principal Investigator</b></p> <p>Dr. Maya Gopalakrishnan</p> <p>Assistant Professor All India Institute of Medical Sciences (AIIMS), Jodhpur- 342005 Rajasthan</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Association for Medical Education in Europe</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 2,01,500</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Neglected Tropical Disease</p>
	Approved .	

S. No.	Details of the Project	
3.	Breast Cancer Hub Epidemiological Research Study	
	<p><b>Principal Investigator</b></p> <p>Dr. Rakesh Swarnamma Ramesh</p> <p>Associate Professor St John's Medical College and Hospital, Bangalore-560032 Karnataka</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Breast Cancer Hub Corporation, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 40,38,000</p> <p><b>Duration</b>                      60 Months</p> <p><b>Subject area</b>                 Oncology</p>
	Approved with conditions.	
4.	To Identify and characterize genes for cardiomyopathies and coronary artery disease	
	<p><b>Principal Investigator</b></p> <p>Dr. Dhandapany Perundurai</p> <p>Assistant Professor Institute for Stem Cell Science and Regenerative Medicine (inStem), Bangalore-560065 Karnataka</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Broad Institute of MIT and Harvard, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 12,65,000 (DBT Wellcome trust Indian alliance intermediate fellowship and inStem internal core grant)</p> <p><b>Duration</b>                      60 Months</p> <p><b>Subject area</b>                 Genomics</p>
	Approved for inStem, Bangalore only. However, i. Only de-identified data be shared with the foreign PI. ii. The appropriate GoI clearances should be obtained for visit of foreign team members (if any) to India.	

S. No.	Details of the Project	
5.	Screening of non-biological synthetic compounds as candidate against mosquito vectors	
	<p><b>Principal Investigator</b></p> <p>Dr. Amit Sharma</p> <p>Scientist G &amp; Director ICMR-National Institute of Malaria Research (ICMR-NIMR), New Delhi-110077</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Broad Institute of MIT and Harvard, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Vector Control</p>
	Approved.	
6.	Field Epidemiology Training Program – Noncommunicable Diseases: Building capacity for noncommunicable disease program implementation in India	
	<p><b>Principal Investigator</b></p> <p>Dr. Prabhdeep Kaur</p> <p>Scientist E ICMR-National Institute of Epidemiology (ICMR-NIE), Chennai-600077 Tamil Nadu</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Centers for Disease Control and Prevention, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 4,67,22,190</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Capacity Building</p>
	Approved after satisfactory response by PI to comments of MEA (GoI). However, the appropriate GoI clearances should be obtained for visit of foreign team members (if any) to India.	

S. No.	Details of the Project	
7.	A Qualitative Study of Traditional Bone Healers in S. India	
	<p><b>Principal Investigator</b></p> <p>Dr. Manjulika Vaz</p> <p>Professor St John's Research Institute, Bangalore-560034 Karnataka</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Clendening-King Summer Fellowships, University of Kansas School of Medicine, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>                Rs. 55,000</p> <p><b>Duration</b>                        2 Months</p> <p><b>Subject area</b>                    Traditional Medicine</p>
	Approved . However, Institutional Ethics Committee (IEC) clearance should be submitted by PI before initiation of the study.	
8.	Immunogenicity, molecular profiling and safety of a marketed quadrivalent influenza vaccine (FluQuadri™) administered by the intramuscular route in participants 60 years of age and older	
	<p><b>Principal Investigator</b></p> <p>Dr. Nithya Jaideep Gogtay</p> <p>Professor and Head Seth G S Medical College and KEM Hospital, Mumbai-400012 Maharashtra</p>	<p><b>Funding/Collaborating Agency</b></p> <p>DBT under Indo-Australian Biotechnology Fund</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>                Rs. 61,11,84,000</p> <p><b>Duration</b>                        24 Months</p> <p><b>Subject area</b>                    Vaccine Development</p>
	Approved after confirmation of co-funding by DBT under the EU-India Cooperation.	

S. No.	Details of the Project	
9.	EPIDEMIOLOGICAL FEATURES AND GEOSPATIAL EVALUATION OF COVID-19: CORRELATION WITH COMORBIDITIES AND PROGNOSTIC BIOMARKERS BETWEEN SARS-CoV-2 AND Mycobacterium tuberculosis	
	<p><b>Principal Investigator</b></p> <p>Dr. Jyotirmayee Turuk</p> <p>Scientist C ICMR-Regional Medical Research Centre (ICMR-RMRC), Bhubaneswar-751023 Orissa</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Department of Science &amp; Technology(DST), India</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 2,11,72,179</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                  COVID-19</p>
	Approved . Due to urgency to start the work (in view of public health emergency), the Chairman, HMSC approved the study on 8 <sup>th</sup> June, 2021. Committee endorsed the decision.	
10.	Validation of a Secure Ultrasound Imaging (Distributed Intelligent Ultrasound Imaging System for Secure Diagnostics: SecureUltrasound), against the Gold Standard	
	<p><b>Principal Investigator</b></p> <p>Dr. Tony D S Raj</p> <p>Dean St John's Research Institute, Bangalore-560034 Karnataka</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Engineering and Physical Sciences Research Council (EPSRC), UK</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 88,07,101</p> <p><b>Duration</b>                      36 Months</p> <p><b>Subject area</b>                  Ultrasound Imaging</p>
	Approved.	

S. No.	Details of the Project	
11.	Validation of the EORTC QLQ-C30 with young people aged 12-17 years with cancer	
	<p><b>Principal Investigator</b></p> <p>Dr. Manjunath Nookalakrishnamurthy</p> <p>Associate Professor Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Mumbai-410210 Maharashtra</p>	<p><b>Funding/Collaborating Agency</b></p> <p>European Organization for Research and Training in Cancer, Belgium</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Oncology</p>
	Approved for TMC, Mumbai only. Copies of the duly signed Research Contract and Data Sharing Agreement should be submitted by PI to ICMR before initiation of the study.	
12.	Silica-related diseases in Rajasthan, India; enhancing prevention	
	<p><b>Principal Investigator</b></p> <p>Dr. Kamalesh Sarkar</p> <p>Scientist G &amp; Director ICMR-National Institute of Occupational Health (ICMR-NIOH), Ahmedabad-380016 Gujrat</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Global Challenge Research Fund</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 58,51,383</p> <p><b>Duration</b>                      8 Months</p> <p><b>Subject area</b>                 Occupational Health</p>
	Approved . Project was granted expedited approval by the Chairman, HMSC on 2 <sup>nd</sup> June, 2021, due to the deadline of the foreign funding agency, subject to submission of Institutional Ethics Committee clearance(s) of ICMR-NIOH, Ahmedabad and AIIMS, Jodhpur to ICMR before initiation of the study. However, the additional comments on the project by Ministry of Environment and Forest through MEA are awaited, which will be shared by MEA for review by ICMR and taken into consideration by PI.	

S. No.	Details of the Project	
13.	Identification of biomarkers for Central Nervous System Tuberculosis (CNS Tb)	
	<p><b>Principal Investigator</b></p> <p>Dr. Jeyaraj Durai Pandian</p> <p>Professor Christian Medical College, Ludhiana-141008 Punjab</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Goethe University, Germany</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 7,62,645</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Neurology</p>
	Approved .	
14.	An epidemiological study to determine the agent, host and environment characteristics for snakebite and factors determining severity of morbidity- A facility based cross-sectional study in Tigiria Block of Cuttack District, Odisha, India	
	<p><b>Principal Investigator</b></p> <p>Dr. Srikanta Kanungo</p> <p>Scientist C ICMR-Regional Medical Research Centre (ICMR-RMRC), Bhubaneswar-751023 Orissa</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Hamish Ogston Foundation, UK</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 5,00,000</p> <p><b>Duration</b>                      6 Months</p> <p><b>Subject area</b>                 Public Health</p>
	Approved subject to the following; i. SAC approval should be submitted to ICMR before initiation of the study. ii. The point mentioned in the IEC clearance regarding confidentiality and consent to be fulfilled by the PI before initiation of the study.	

S. No.	Details of the Project	
15.	CAPHER-Collaborative on Air Pollution and Health Effects Research, India	
	<p><b>Principal Investigator</b></p> <p>Dr. Harshal Ramesh Salve</p> <p>Associate Professor All India Institute of Medical Sciences (AIIMS), New Delhi-110029</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Health Effects Institute (HEI), USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 48,81,800</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Environmental Health</p>
	Approved . However, a copy of signed Professional Service Agreement should be shared with ICMR.	
16.	Extended blood group phenotyping of blood donors at JIPMER and build a hospital-based “Rare Donor Registry.”	
	<p><b>Principal Investigator</b></p> <p>Dr. Abhishekh Basavarajegowda</p> <p>Associate Professor Jawaharlal Institute of Post Graduate Medical Education and Research (JIPMER), Puducherry-605006</p>	<p><b>Funding/Collaborating Agency</b></p> <p>JIPMER Alumni Association of North America (JAANA), USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 55,000</p> <p><b>Duration</b>                      12 Months</p> <p><b>Subject area</b>                 Transfusion Medicine</p>
	Approved . However, the duly valid Institutional Ethics Committee (IEC) clearance should be submitted to ICMR before initiation of the study.	



S. No.	Details of the Project	
17.	CardiOvaScular and Pulmonary Mechanisms In Covid-19 in India: A multimodality imaging study (COSMIC-INDIA Study)	
	<p><b>Principal Investigator</b></p> <p>Dr. Narasimhan Calambur</p> <p>Consultant Asian Institute of Gastroenterology, Hyderabad-500082 Telangana</p>	<p><b>Funding/Collaborating Agency</b></p> <p>London School of Hygiene &amp; Tropical Medicine (LSHTM), UK-UKRI,MRC,UK</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 5,86,76,530</p> <p><b>Duration</b>                      18 Months</p> <p><b>Subject area</b>                  COVID-19</p>
	Approved . However, a copy of the FCRA clearance (as already requested from PI) should be submitted to ICMR before initiation of the study.	
18.	Interact 3-INTensive care bundle with blood pressure Reduction in Acute Cerebral haemorrhage Trial	
	<p><b>Principal Investigator</b></p> <p>Dr. Jeyaraj Durai Pandian</p> <p>Professor Christian Medical College, Ludhiana-141008 Punjab</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Medical Research Council (MRC), UK</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 70,73,372</p> <p><b>Duration</b>                      48 Months</p> <p><b>Subject area</b>                  Neurology</p>
	Approved for 7 sites only. The Institutional Ethics Committee clearances for remaining 2 sites should be submitted to ICMR before initiation of the study.	

S. No.	Details of the Project	
19.	Machine learning in the determination of complete tumor response in patients with significant amount of mucin on MRI after neoadjuvant therapy	
	<p><b>Principal Investigator</b></p> <p>Dr. Akshay Baheti</p> <p>Associate Professor Tata Memorial Hospital, Mumbai-400012 Maharashtra</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Memorial Sloan Kettering Cancer Center, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      18 Months</p> <p><b>Subject area</b>                 Gastroenterology</p>
	Approved . However, a copy of MoU should be submitted to ICMR before initiation of the study.	
20.	International Collaborative Study on Patients with Sinonasal and Skull Base Malignancies	
	<p><b>Principal Investigator</b></p> <p>Prof. Prathamesh S Pai</p> <p>Professor Tata Memorial Hospital, Mumbai-400012 Maharashtra</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Memorial Sloan Kettering Cancer Center, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      12 Months</p> <p><b>Subject area</b>                 Oncology</p>
	Approved .	

S. No.	Details of the Project	
21.	A study of HCC correlating its biology with Clinico demographic and ethnic features along with its Survival outcomes	
	<p><b>Principal Investigator</b></p> <p>Dr. Vikas Sureshchand Ostwal</p> <p>Professor Tata Memorial Hospital, Mumbai-4177000 Maharashtra</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Memorial Sloan Kettering Cancer Weill Medical College at Cornell University, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 2,383,000 (TMH)</p> <p><b>Duration</b>                      36 Months</p> <p><b>Subject area</b>                  Oncology</p>
	Approved .	
22.	Scaling up tobacco control in India: Comparing smartphone to in-person training for implementing an evidence-based intervention to reduce tobacco use among school teachers	
	<p><b>Principal Investigator</b></p> <p>Dr. Mangesh Suryakant Pednekar</p> <p>Director Healis Sekhsaria Institute for Public Health, Navi Mumbai-400701 Maharashtra</p>	<p><b>Funding/Collaborating Agency</b></p> <p>National Institutes of Health (NIH), USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 3,54,57,589</p> <p><b>Duration</b>                      48 Months</p> <p><b>Subject area</b>                  Tobacco</p>
	Approved , subject to renewal & submission of FCRA beyond 31-10-2021 & Institutional Ethics Committee clearance after first year.	

S. No.	Details of the Project	
23.	Exploring Reasons for Why Health Care Providers Do Not Treat Child Diarrhea Appropriately in the Private Sector Using Standardized Patients	
	<p><b>Principal Investigator</b></p> <p>Dr. Arnab Mukherji</p> <p>Professor Indian Institute of Management, Bangalore-560076 Karnataka</p>	<p><b>Funding/Collaborating Agency</b></p> <p>National Institutes of Health (NIH), USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 79,79,669</p> <p><b>Duration</b>                      48 Months</p> <p><b>Subject area</b>                 Child Health</p>
	Approved based on clarifications provided by PI, which were found to be satisfactory by CTD Division of MOH&FW. However, necessary GoI permission for foreign PI's visit to several places in Karnataka, Bihar & Gujarat be obtained prior to the visits.	
24.	ACTIV-2/A5401 Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)	
	<p><b>Principal Investigator</b></p> <p>Prof. Shashikala Anant Sangle</p> <p>Professor B J Medical College, Pune-411001 Maharashtra</p>	<p><b>Funding/Collaborating Agency</b></p> <p>National Institutes of Health (NIH), USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 29,79,760</p> <p><b>Duration</b>                      72 Weeks</p> <p><b>Subject area</b>                 COVID-19</p>
	Approved . Due to the urgency to start the work (in view of public health emergency), the Chairman, HMSC granted expedited approval for the study on 16 <sup>th</sup> June, 2021. However, the study should only be initiated at 3 sites (out of 15 sites) after submission.	

S. No.	Details of the Project	
25.	Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR) Study	
	<p><b>Principal Investigator</b></p> <p>Dr. Venkatesh Prajna Namperumalsamy</p> <p>Director Aravind Eye Hospital &amp; PG Institute of Ophthalmology, Madurai-625020 Tamil Nadu</p>	<p><b>Funding/Collaborating Agency</b></p> <p>National Institutes of Health (NIH), USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 1,23,75,000</p> <p><b>Duration</b>                      48 Months</p> <p><b>Subject area</b>                  Ophthalmology</p>
	Approved . However, the appropriate GoI clearances should be obtained for visit of foreign team members (if any) to India.	
26.	Yoga for Healthy Aging (YHA) Study: A Mind-Body Intervention to Reduce Multimorbidity In the Elderly	
	<p><b>Principal Investigator</b></p> <p>Dr. Vijaya Srinivas</p> <p>Senior Research Physician Public Health Research Institute of India, Mysore-570020 Karnataka</p>	<p><b>Funding/Collaborating Agency</b></p> <p>National Institutes of Health (NIH), USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 55,63,132</p> <p><b>Duration</b>                      36 Months</p> <p><b>Subject area</b>                  Public Health</p>
	Approved on the basis of clarifications received by PI, which were found to be satisfactory by the Scientific Division. Proposal was earlier not approved in the HMSC meeting held on 24 <sup>th</sup> February, 2021.	

S. No.	Details of the Project	
27.	A5362 A Phase IIc Trial of Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study	
	<p><b>Principal Investigator</b></p> <p>Dr. Rahul Maruti Lokhande</p> <p>Associate Professor B J Medical College, Pune-411001 Maharashtra</p>	<p><b>Funding/Collaborating Agency</b></p> <p>National Institutes of Health (NIH), USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 90,86,545</p> <p><b>Duration</b>                      15 Months</p> <p><b>Subject area</b>                 Tuberculosis</p>
	Approved . However, the appropriate GoI clearances should be obtained for visit of foreign team members (if any) to India.	
28.	Phase I study of Topotecan combined with Dexamethasone and Remdesivir to reduce systemic inflammation in cancer patients with COVID-19	
	<p><b>Principal Investigator</b></p> <p>Dr. Ajoy Oommen John</p> <p>Assistant Professor Christian Medical College and Hospital, Vellore-632004 Tamil Nadu</p>	<p><b>Funding/Collaborating Agency</b></p> <p>National University of Health Sciences, Singapore</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 16,25,180</p> <p><b>Duration</b>                      12 Months</p> <p><b>Subject area</b>                 COVID-19</p>
	Approved . Due to the urgency to start the work (in view of public health emergency), the Chairman, HMSC granted expedited approval for the study on 30 <sup>th</sup> June, 2021. The Committee endorsed the decision.	

S. No.	Details of the Project	
29.	Reducing stigma and improving mental wellbeing and social participation amongst men and women affected/disabled by lymphatic filariasis and leprosy in the districts of Jaunpur and Bokaro in India	
	<p><b>Principal Investigator</b></p> <p>Dr. Chandra Pati Mishra</p> <p>Professor Institute of Medical sciences (BHU), Varanasi-221005 Uttar Pradesh</p>	<p><b>Funding/Collaborating Agency</b></p> <p>NLR Netherlands</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 1,53,86,683</p> <p><b>Duration</b>                      15 Months</p> <p><b>Subject area</b>                 Mental Health</p>
	Approved .	
30.	Genomic profiling to decode novel mutations for early diagnosis of ovarian cancer	
	<p><b>Principal Investigator</b></p> <p>Dr. Amar Ranjan Singh</p> <p>Additional Professor All India Institute of Medical Sciences (AIIMS), New Delhi-110029</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Rivkin Center for Ovarian Cancer, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 54,60,559</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Oncology</p>
	Approved . However, the valid Institutional Ethics Committee (IEC) clearance should be submitted to ICMR before initiation of the study.	

S. No.	Details of the Project	
31.	International Snapshot Study on the Outcomes of Pancreatic Surgery - PancreasGroup.org	
	<p><b>Principal Investigator</b></p> <p>Prof. Sanjeev Misra</p> <p>Professor All India Institute of Medical Science (AIIMS), Jodhpur-342005 Rajasthan</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Royal Free Hospital, London, UK</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      12 Months</p> <p><b>Subject area</b>                 Oncology</p>
	Approved with conditions.	
32.	Climate, Health and Air pollution Research in India (CHAIR-India): Addressing Gaps in Achieving the Sustainable Development Goals	
	<p><b>Principal Investigator</b></p> <p>Dr. Poornima Prabhakaran</p> <p>Head Public Health Foundation of India, Gurgaon-122002, Haryana</p>	<p><b>Funding/Collaborating Agency</b></p> <p>Swedish Research Council , Sweden</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 3,43,77,697</p> <p><b>Duration</b>                      48 Months</p> <p><b>Subject area</b>                 Environmental Health</p>
	Approved.	



S. No.	Details of the Project	
33.	ARCA-1 study: perioperative caRe in the Cancer patient-1	
	<p><b>Principal Investigator</b></p> <p>Dr. Sushma Bhatnagar</p> <p>Professor All India Institute of Medical Sciences (AIIMS), New Delhi-110029</p>	<p><b>Funding/Collaborating Agency</b></p> <p>The University of Texas MD Anderson Cancer Center, USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Oncology</p>
	Approved . However, the Institutional Ethics Committee clearance and copy of MoU between AIIMS, New Delhi & University of Texas should be submitted by PI to ICMR before initiation of the study.	
34.	Improving ROP Telemedicine Systems in South India	
	<p><b>Principal Investigator</b></p> <p>Dr. Parag Kirit Shah</p> <p>Medical Consultant Aravind Eye Hospital, Coimbatore-641014 Tamil Nadu</p>	<p><b>Funding/Collaborating Agency</b></p> <p>United States Agency for International Development (USAID), USA</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Rs. 2,53,86,771</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Ophthalmology</p>
	Approved . However the Institutional Ethics Committee clearance of Yenepova research centre, Mangalore site should be submitted to ICMR before initiation of the study. The appropriate GoI clearances should be obtained for visit of foreign team members (if any) to India.	

S. No.	Details of the Project	
35.	Eagle: ESCP Safe Anastomosis Programme In Colorectal Surgery	
	<p><b>Principal Investigator</b></p> <p>Prof. Parvez David Haque</p> <p>Professor Christian Medical College, Ludhiana-141008 Punjab</p>	<p><b>Funding/Collaborating Agency</b></p> <p>University of Birmingham, UK</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      12 Months</p> <p><b>Subject area</b>                 Colorectal Surgery</p>
	Approved only for 15 sites having Institutional Ethics Committee clearance. For other sites (JOSH, Manglaore; Synergy, Dehradun and AIIMS, Jodhpur) study should only be initiated after submission of IEC clearances to ICMR.	
36.	Improving Appropriate Access and Availability of Opioids for Cancer-related Pain Control in India (IMPOP): bridging the gap between policy and practice	
	<p><b>Principal Investigator</b></p> <p>Prof. Naveen Salins</p> <p>Professor Kasturba Medical College and Hospital, Manipal-576104 Karnataka</p>	<p><b>Funding/Collaborating Agency</b></p> <p>University of Hull, UK</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      3 Months</p> <p><b>Subject area</b>                 Capacity Building</p>
	Approved with conditions.	

S. No.	Details of the Project	
37.	Health-Related Quality of Life and Survivorship in Locally Recurrent Rectal Cancer. The LRRC-QoL Study	
	<p><b>Principal Investigator</b></p> <p>Dr. Asif Mehraj</p> <p>Professor Sher-i-Kashmir Institute of Medical Sciences, Srinagar-190011 Jammu and Kashmir</p>	<p><b>Funding/Collaborating Agency</b></p> <p>University of Leeds, UK</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      24 Months</p> <p><b>Subject area</b>                 Oncology</p>
	Approved for 2 centres only i.e. Sher I Kashmir Institute of Medical Sciences, Srinagar; Basavatarakam Indo American Cancer Institute, Hyderabad. The Institutional Ethics Committee clearance for remaining 1 site should be submitted to ICMR before initiation of the study.	
38.	Multi-centric collaborative study to assess the outcomes of endoscopically-treated sinonasal malignancies	
	<p><b>Principal Investigator</b></p> <p>Prof. Prathamesh S Pai</p> <p>Professor Tata Memorial Hospital, Mumbai-400012 Maharashtra</p>	<p><b>Funding/Collaborating Agency</b></p> <p>University of Padua, Italy</p> <p><b>Date of approval</b>      July 13, 2021</p> <p><b>Total budget</b>              Nil</p> <p><b>Duration</b>                      12 Months</p> <p><b>Subject area</b>                 Oncology</p>
	Approved .	